Japanese investment firm makes additional investment in Eyegenex for new treatment to prevent blindness
Japanese investment firm "Newsight Tech Angels" has announced an additional investment in "Eyegenex," a company developing treatments for eye diseases that lead to blindness, such as glaucoma. This investment aims to support the development of innovative medical technologies.
Currently, common treatments for conditions like glaucoma involve using eye drops or surgery to lower intraocular pressure. However, these methods are intended to slow the progression of the disease, and it is currently difficult to fully restore vision or optic nerves once they have been lost.
Eyegenex, the recipient of this support, is working on a new treatment method that differs from existing symptomatic therapies. The company aims to restore lost visual fields and optic nerves, garnering significant expectations from patients around the world.
This additional investment is expected to further accelerate Eyegenex's research and development. If this new treatment is successfully commercialized, it will serve as a beacon of hope for many patients. Attention remains focused on how Japanese companies will continue to support cutting-edge medical care globally.